Effects of down-regulation of HDAC6 Expression on proliferation,: Cell cycling and migration of esophageal squamous cell: Carcinoma cells and related molecular mechanisms

Asian Pacific Journal of Cancer Prevention

Volumn 14, Issue 2, 2013, Pages 685-689

  Li, Ning ^a   Tie, Xiao Jing ^a   Liu, Pei Jie ^a   Zhang, Yan ^a   Ren, Hong Zheng ^a   Gao, Xin ^a   Xu, Zhi Qiao ^a  

^a First People's Hospital of Kaifeng   (China)

Author keywords

Esophageal squamous cell carcinoma HDAC6 cell proliferation cell cycle cell migration p21 E cadherin

Indexed keywords

CADHERIN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; HDAC6 PROTEIN, HUMAN; HISTONE DEACETYLASE; MESSENGER RNA; SMALL INTERFERING RNA;

ARTICLE; BIOSYNTHESIS; CELL CYCLE; CELL MOTION; CELL PROLIFERATION; DNA REPLICATION; DOWN REGULATION; ESOPHAGUS TUMOR; G1 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION; GENETICS; HUMAN; METABOLISM; RNA INTERFERENCE; SQUAMOUS CELL CARCINOMA; TUMOR CELL LINE;

CADHERINS; CELL CYCLE; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DNA REPLICATION; DOWN-REGULATION; ESOPHAGEAL NEOPLASMS; G1 PHASE CELL CYCLE CHECKPOINTS; GENE EXPRESSION; HISTONE DEACETYLASES; HUMANS; NEOPLASMS, SQUAMOUS CELL; RNA INTERFERENCE; RNA, MESSENGER; RNA, SMALL INTERFERING;

EID: 84877682700     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2013.14.2.685     Document Type: Article

References (33)

1. Ai J, Wang Y, Dar JA, et al. (2009). HDAC6 regulates androgen receptor hypersensitivity and nuclear localization via modulating Hsp90 acetylation in castration-resistant prostate cancer. Mol Endocrinol, 23, 1963-72.
2. Baker M (2010). RNA interference: Homing in on delivery. Nature, 464, 1225-8.
3. Banerjee HN, Verma M (2009). Epigenetic mechanisms in cancer. Biomark Med, 3, 397-410.
4. Barnes PJ, Adcock IM (2009). Glucocorticoid resistance in inflammatory diseases. Ancet, 373, l905-l7.
5. Carew JS, Giles FJ, Nawrocki ST (2008). Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy. Cancer Lett, 269, 7-17.
6. Carter CL, Lin C, Liu CY, et al. (2010). Phosphorylated p68 RNA helicase activates Snail1 transcription by promoting HDAC1 dissociation from the Snail1 promoter. Oncogene, 29, 5427-36.
7. Chen J, Zhou H, Li Q, et al. (2011). Epigenetic modification of RhoE expression in gastric cancer cells. Oncol Rep, 25, 173-80.
8. Duong V, Bret C, Altucci L, et al. (2008). Specific activity of class II histone deacetylases in human breast cancer cells. Mol Cancer Res, 6, 1908-19.
9. Fan LH, Li LX, Wei YC (2006). The Value of Immunocytochemistry in the Cytological Diagnosis of Serous Ef fusion. J Mod Lb Med, 21, 6-8.
10. He QX, Zhu QJ, Chen JO, et al. (2006). Application of immunocytochemistry to cytological diagnosis in hydrothorax and ascites. J Wenzhou Med College, 36, 466-8.
11. Hideshima T, Bradner JE, Wong J, et al. (2005). Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proc Natl Acad Sci USA, 102, 8567-72.
12. Hrzenjak A, Moinfar F, Kremser ML, et al. (2005). Valproate inhibition of histone deacetylase 2 affects differentiation and decreases proliferation of endometrial stromal sarcoma cells. Mol Cancer Ther, 5, 2203-10.
13. Husain M, Harrod KS (2009). Influenza A virus-induced caspase-3 cleaves the histone deacetylase 6 in infected epithelial cells. FEBS Lett, 583, 2517-20.
14. Jiang XX, Zhang QL,Wu WL, et al. (2009). Synergistic effects of proteasome inhibitor and Histone Deacetylase Inhibitor on apoptosis and aggresome formation in T Lymphoma cells. J Experim Hematol, 17, 1232-6.
15. Kakihana M, Ohira T, Chan D, et al. (2009). Induction of E-cadherin in lung cancer and interaction with growth suppression by histone deacetylase inhibition. J Thorac Oncol, 4, 1455-65.
16. Kawaguchi Y, Kovacs JJ, McLaurin A, et al. (2003). The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress. Cell, 115, 727-38.
17. Kuwano H, Watanabe M, Sadanaga N, et al. (1993). Squamous epithelial dysplasia associated with squamous cell carcinoma of the esophagus. Cancer Lett, 72, 141-7.
18. Parkin DM (2000). Global cancer statistics in the year 2000. Lancet Oncol, 2, 533-43.
19. Parkin DM, Bray FI, Devesa SS (2001). Cancer burden in the year 2000. The global picture. Eur J Cancer, 8, S4-66.
20. Rey M, Irondelle M, Waharte F, et al. (2010). HDAC6 is required for invadopodia activity and invasion by breast tumor cells. Eur J Cell Biol, 12, 25-30.
21. Sakuma T, Uzawa K, Onda T, et al. (2006). Aberrant expression of histone deacetylase 6 in oral squamous cell carcinoma. Int J Oncol, 29, 117-24.
22. Shen J, Wang WQ (2011). Enhancement of sensitivity of oral squamous carcinoma cells to cytochrome c mediated apoptosis by histone deacetylase inhibitors. J Med Res, 40, 62-6.
23. Shen R, Chinnaiyan AM, Ghosh D (2008). Pathway analysis reveals function al convergence of gene expression profiles in breast cancer. BMC Med Genomics, 1, 28.
24. Unoki M (2011). Current and Potential Anticancer Drugs Targeting Members of the UHRF1 Complex Including Epigenetic Modifiers. Recent Pat Anticancer Drug Discov, 6, 116-30.
25. Westendorf JJ, Zaidi SK, Cascino JE, et al. (2002). Runx2 (Cbfa1, AML-3) interacts with histone deacetylase 6 and represses the p21(CIP1/WAF1) promoter. Mol Cell Biol, 22, 7982-92.
26. Wilson AJ, Byun DS, Popova N, et al. (2006). Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer. J Biol Chem, 281, 13548-58.
27. Wu Y, Song SW, Sun J, et al. (2010). IIp45 inhibits cell migration through inhibition of HDAC6. J Biol Chem, 285, 3554-60.
28. Xu C, Lee SA, Chen X (2011). RNA interference as therapeutics for hepatocellular carcinoma. Recent Pat Anticancer Drug Discov, 6, 105-15.
29. Yuan Q, Ye YJ, Fan YS (2006). The application of i mmunocy to chemistry markers in cytological differential diagnosis of effusi on smear. 1, 50-3.
30. Zhang H, Chen SH, Li YM (2004). Epidemiological investigation of esophageal carcinoma. World J Gastroenterol, 10, 1834-5.
31. Zhang J, He Y, Wand SK, et al. (2012). Expression of E-cadherin in the tumor tissue and serum of patients with esophageal squamous cell carcinoma. J Central South Univ (Medical Science), 3, 228-32.
32. Zhang XG, Li Z, Wang JF, et al. (2009). Evaluation of risk factors and prevention strategies of esophageal cancer. World Chinese J Digestol, 17, 677-80.
33. Zhang ZH, Zhao LL, Guo HQ, et al. (2008). Application of thin-layer cytology smears and immunocytochemistry in identifying the cell types of malignant tumors. JOURNAL??? 35, 332-5.